FIELD: biotechnology.
SUBSTANCE: invention relates to a cell containing an exogenous nucleic acid, which provides expression or overexpression of a clostridial neurotoxin receptor or a variant thereof, or a fragment thereof, which has the ability to bind clostridial neurotoxin, an exogenous nucleic acid which provides expression or overexpression of a ganglioside having a clostridial neurotoxin binding affinity, and an exogenous nucleic acid which provides expression or overexpression of an indicator protein cleaved by a clostridial neurotoxin, as well as a method for production thereof.
EFFECT: invention is effective for identifying the composition of Clostridial neurotoxin for therapeutic and cosmetic use, for characterizing the activity of the composition of Clostridial neurotoxin, as well as for analysis for determining activity of modified or recombinant neurotoxin.
42 cl, 13 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CELLS HIGHLY SENSITIVE TO CLOSTRIDIAL NEUROTOXIN | 2020 |
|
RU2831112C2 |
| TREATMENT OF SKIN DISEASES | 2021 |
|
RU2840027C1 |
| NON-TOXIC POLYPEPTIDES OF CLOSTRIDIAL NEUROTOXIN FOR USE IN TREATING NEUROLOGICAL DISORDERS | 2020 |
|
RU2839368C1 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| MODIFIED BOTULINUM NEUROTOXIN FOR TREATING EXTREMITY SPASTICITY | 2021 |
|
RU2841585C1 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2019 |
|
RU2727402C1 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
